Calcification characteristics of low-flow low-gradient severe aortic stenosis in patients undergoing transcatheter aortic valve replacement by Stähli, Barbara E et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Calcification characteristics of low-flow low-gradient severe aortic stenosis in
patients undergoing transcatheter aortic valve replacement
Stähli, Barbara E; Nguyen-Kim, Thi Dan Linh; Gebhard, Cathérine; Frauenfelder, Thomas; Tanner,
Felix C; Nietlispach, Fabian; Maisano, Francesco; Falk, Volkmar; Lüscher, Thomas F; Maier, Willibald;
Binder, Ronald K
Abstract: Low-flow low-gradient severe aortic stenosis (LFLGAS) is associated with worse outcomes. Aor-
tic valve calcification patterns of LFLGAS as compared to non-LFLGAS have not yet been thoroughly
assessed. 137 patients undergoing transcatheter aortic valve replacement (TAVR) with preprocedural
multidetector computed tomography (MDCT) and postprocedural transthoracic echocardiography were
enrolled. Calcification characteristics were assessed by MDCT both for the total aortic valve and sepa-
rately for each leaflet. 34 patients had LFLGAS and 103 non-LFLGAS. Total aortic valve calcification
volume (p < 0.001), mass (p < 0.001), and density (p = 0.004) were lower in LFLGAS as compared to
non-LFLGAS patients. At 30-day follow-up, mean transaortic pressure gradients and more than mild
paravalvular regurgitation did not differ between groups. In conclusion, LFLGAS and non-LFLGAS
express different calcification patterns which, however, did not impact on device success after TAVR.
DOI: 10.1155/2015/802840
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-118336
Published Version
 
 
Originally published at:
Stähli, Barbara E; Nguyen-Kim, Thi Dan Linh; Gebhard, Cathérine; Frauenfelder, Thomas; Tanner, Felix
C; Nietlispach, Fabian; Maisano, Francesco; Falk, Volkmar; Lüscher, Thomas F; Maier, Willibald; Binder,
Ronald K (2015). Calcification characteristics of low-flow low-gradient severe aortic stenosis in patients
undergoing transcatheter aortic valve replacement. Cardiology Research and Practice, 2015(802840):on-
line. DOI: 10.1155/2015/802840
Research Article
Calcification Characteristics of Low-Flow Low-Gradient
Severe Aortic Stenosis in Patients Undergoing Transcatheter
Aortic Valve Replacement
Barbara E. Stähli,1 Thi Dan Linh Nguyen-Kim,2 Cathérine Gebhard,1
Thomas Frauenfelder,2 Felix C. Tanner,1 Fabian Nietlispach,1 Francesco Maisano,3
Volkmar Falk,3 Thomas F. Lüscher,1 Willibald Maier,1 and Ronald K. Binder1
1University Heart Center, Department of Cardiology, University Hospital Zu¨rich, 8091 Zu¨rich, Switzerland
2Institute of Diagnostic and Interventional Radiology, University Hospital Zu¨rich, 8091 Zu¨rich, Switzerland
3University Heart Center, Department of Cardiovascular Surgery, University Hospital Zu¨rich, 8091 Zu¨rich, Switzerland
Correspondence should be addressed to Ronald K. Binder; ronald.binder@usz.ch
Received 24 June 2015; Accepted 20 August 2015
Academic Editor: G. Thiene
Copyright © 2015 Barbara E. Sta¨hli et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Low-flow low-gradient severe aortic stenosis (LFLGAS) is associated with worse outcomes. Aortic valve calcification patterns
of LFLGAS as compared to non-LFLGAS have not yet been thoroughly assessed. 137 patients undergoing transcatheter aortic
valve replacement (TAVR) with preprocedural multidetector computed tomography (MDCT) and postprocedural transthoracic
echocardiography were enrolled. Calcification characteristics were assessed byMDCT both for the total aortic valve and separately
for each leaflet. 34 patients had LFLGAS and 103 non-LFLGAS. Total aortic valve calcification volume (𝑝 < 0.001),mass (𝑝 < 0.001),
and density (𝑝 = 0.004) were lower in LFLGAS as compared to non-LFLGAS patients. At 30-day follow-up, mean transaortic
pressure gradients and more than mild paravalvular regurgitation did not differ between groups. In conclusion, LFLGAS and non-
LFLGAS express different calcification patterns which, however, did not impact on device success after TAVR.
1. Introduction
Severe aortic stenosis (AS) is themost frequent valvular heart
disease in the Western society [1, 2], and surgical aortic valve
replacement (SAVR) has been the standard treatment once
symptoms appear [3, 4]. However, treatment of high-risk
patient subpopulations including those with low-flow low-
gradient severe aortic stenosis (LFLGAS) remains challeng-
ing given their dismal prognosis when treated conservatively
and the high surgical risk [5, 6]. Although SAVR has been
associated with better clinical outcomes compared tomedical
management in LFLGAS [7, 8], the associated surgical risk
may be prohibitive, and transcatheter aortic valve replace-
ment (TAVR) has become a less invasive treatment option in
high-risk patients [3, 9–11].
Aortic valve calcifications have extensively been stud-
ied in patients undergoing TAVR, and annular assessment
is mostly based on multidetector computed tomography
(MDCT) or transesophageal echocardiography [12, 13]. As
degenerative aortic valves often display severe calcifications
affecting the entire aortic root, a thorough preprocedural
evaluation of annular dimensions and calcification charac-
teristics is important for optimal device selection and tran-
scatheter heart valve (THV) positioning, [14, 15]. However,
there exists only few data about calcification patterns in
patients with LFLGAS [16], and comparisons among different
types of AS disease entities have not been performed yet.
The aim of this study was to assess aortic valve calci-
fication characteristics in LFLGAS in comparison to non-
LFLGAS patients and to delineate their impact on postpro-
cedural THV function.
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2. Materials and Methods
2.1. Patients and Procedures. Patients with symptomatic
severe AS (mean transaortic systolic pressure gradient of
≥40mmHg or an aortic valve area (AVA) of <1.0 cm2 or
<0.6 cm2/m2) and both comprehensive baseline MDCT and
postprocedural echocardiographic exams within 30 days
were included in the analysis. Patients were then subdi-
vided into two groups: (1) patients with LFLGAS (stroke
volume index ≤35mL/m2 and mean aortic valve gradient
≤40mmHg), including patients with preserved (paradoxi-
cal LFLGAS) and reduced left ventricular ejection fraction
(LVEF), and (2) patients with non-LFLGAS [17]. All patients
were evaluated for TAVR by a multidisciplinary heart team.
Transthoracic echocardiography studies were performed
at baseline and within 30 days after the procedure using
commercially available equipment (Philips iE33, Philips
Healthcare, Andover, MA, USA; GE Vivid 7, GE Healthcare,
Milwaukee, WI, USA), and in accordance with the recom-
mendations of the American Society of Echocardiography
(ASE) and the European Association of Echocardiography
(EAE) [18].
Transcatheter aortic valve procedures were performed
between May 2008 and April 2012, either in the cardiac
catheterization laboratory or the hybrid operation room, uti-
lizing the Medtronic CoreValve (MCV; 26, 29, and 31mm) or
the Edwards SAPIEN prostheses (ES; 23, 26, and 29mm) [19–
21]. The study was approved by the local ethical committee,
and informed written consent was obtained from all patients.
2.2. Multidetector Computed Tomography (MDCT) Image
Acquisition and Analysis. Multidetector computed tomog-
raphy (MDCT) with craniocaudal scan direction was per-
formed using a second-generation 128-slice dual-source
computed tomography (Somatom Definition Flash, Siemens
Healthcare, Forchheim, Germany). A first bolus of 45mL
of Iopromide (Ultravist 300, 300mg/mL, Bayer Schering
Pharma, Berlin, Germany) was injected at a flow rate of
5mL/sec, followed by a second bolus of 35mL at a flow rate
of 2.5mL/sec and a bolus of 60mL saline at the same flow
rate. A signal attenuation threshold of 100 Hounsfield units
(HU) was used for bolus tracking in the ascending aorta.The
scan ranged from the apex of the lungs to the symphysis and
was started automatically based on the previous 10 heart beats
aiming at a 60% RR-interval at the level of the sinotubular
junction.
As previously described, a dedicated software (3mensio
Structural Heart 6.0, Bilthoven, Netherlands) was utilized
for quantitative image analysis [20]. First, the centerline of
the aortic root and the ascending aorta was drawn semi-
automatically. Then, the aortic annular plane was defined
at the insertion of the aortic leaflets. Calcification charac-
teristics, including calcification volume, mass, and density
(Hounsfield units, HU), were assessed semiautomatically for
the total aortic valve as well as separately for each leaflet
[20]. To determine aortic valve calcification asymmetry, the
maximal difference of both calcification mass and volume
between the three aortic cups was calculated (Figure 1).
The aortic annular eccentricity index was calculated as 1 −
diameterminimal/diametermaximal as previously described [22].
Multidetector computed tomography images were analyzed
by experienced imaging specialists who were blinded to
echocardiographic and clinical data.
2.3. Statistical Analysis. Continuous variables are presented
as means ± standard errors and categorical variables as
frequencies and percentages. Normality distribution was
testedwith the ShapiroWilk test and homogeneity of variance
with the Levene test, respectively. Continuous variables were
tested for differences with the unpaired Student 𝑡-test or
the Mann-Whitney 𝑈 test and categorical variables with the
Pearson 𝜒2 test or the Fisher exact test as appropriate. Corre-
lations between two variables were specified by the Spearman
correlation coefficient. All tests were 2-tailed, and a 𝑝 value of
<0.05 was established as the level of statistical significance for
all tests. All statistical analyses were performed using IBM-
SPSS version 21 (IBM Corp.) for Windows.
3. Results
3.1. Baseline Characteristics. Thirty-four (25%) patients had
LFLGAS and 103 (75%) non-LFLGAS, respectively. Out of the
34 patients with LFLGAS, 18 (53%) patients had preserved
LVEF >50% (paradoxical LFLGAS). All patients were at
increased surgical risk as expressed by a mean Society of
Thoracic Surgeons Predicted Risk of Mortality (STS-PROM)
score of 5.6 ± 0.3%. Peripheral vascular disease and atrial fib-
rillation were more frequently observed in LFLGAS patients
(Table 1).
Mean aortic valve gradientwas 29±1.2mmHg in LFLGAS
patients and 55 ± 1.4mmHg in non-LFLGAS patients (𝑝 <
0.001), and stroke volume index was 27±0.9mL/m2 and 32±
1.1mL/m2 in both groups (𝑝 = 0.009). Aortic valve area was
0.81 ± 0.04 cm2 in LFLGAS patients and 0.69 ± 0.02 cm2 in
non-LFLGAS patients, respectively (𝑝 = 0.004).
3.2. Procedural Characteristics. Transfemoral procedures
were performed in 26 (77%) LFLGAS and in 84 (82%) non-
LFLGAS patients (𝑝 = 0.62), and the MCV prosthesis was
utilized in 19 (56%) LFLGAS and in 49 (48%) non-LFLGAS
patients, respectively (𝑝 = 0.43). Device success at 72 hours
was achieved in 31 (91%) patients in the LFLGAS group and
in 92 (89%) patients in the non-LFLGAS group (𝑝 = 1.0).
Failed device success was due to more than mild aortic
regurgitation in 13 patients and due to an increased mean
transvalvular pressure gradient >20mmHg in 1 patient.
3.3. Aortic Annulus Dimensions Assessed byMDCT. Annulus
area and perimeter were 5.04 ± 0.19 cm2 and 81.1 ± 1.5mm
in patients with LFLGAS and 4.86 ± 0.09 cm2 and 79.7 ± 0.8
in those with non-LFLGAS, without any differences between
groups (𝑝 = 0.31 for annulus area and 𝑝 = 0.36 for annulus
perimeter). Eccentricity index was similar in both groups
(0.22 ± 0.01 for LFLGAS and 0.19 ± 0.01 for non-LFLGAS;
𝑝 = 0.08).
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Figure 1: Multidetector computed tomography (MDCT) analysis illustrating calcification measurements. (a) Centerline of the aortic root
and the ascending aorta. (b), (c), and (d) Anchor points at the level of the insertion of the aortic leaflets. (e) Measurement of calcification
volume and mass.
3.4. Aortic Valve Calcification Pattern Assessed by MDCT. In
the total patient cohort, aortic valves were severely calcified
with a total aortic valve calcification volume of 1106 ±
164mm3, a total aortic valve calcification mass of 660 ±
34mg, and a total aortic valve calcification density of 817 ±
10HU. Total aortic valve calcification volume was 627 ±
61mm3 in LFLGAS versus 1264 ± 216mm3 in non-LFLGAS
(𝑝 < 0.001) and total aortic valve calcification mass was
398 ± 39mg in LFLGAS versus 747 ± 41mg in non-LFLGAS
(𝑝 < 0.001, Table 2). Total aortic valve calcification density
was lower in LFLGAS (766 ± 18HU) compared to non-
LFLGAS (834 ± 12HU; 𝑝 = 0.004). Regarding each leaflet
separately, calcification characteristics differed significantly
for the noncoronary, the left, and the right coronary cusps,
with lower values for LFLGAS compared to non-LFLGAS
(Table 2).
After the exclusion of patients with preserved LVEF>50%
(paradoxical LFLGAS), total aortic valve calcification volume
was 710 ± 107mm3 and 1264 ± 216mm3 in true LFLGAS
and non-LFLGAS patients (𝑝 = 0.01); total aortic valve
calcification mass was 449 ± 69mg and 747 ± 41mg (𝑝 =
0.005) and total aortic valve calcification density 753±28HU
and 834 ± 12HU (𝑝 = 0.02), respectively. In LFLGAS
patients matched for AVA to 34 non-LFLGAS patients,
similar trends were observed, without, however, reaching
statistical significance. In the matched patient cohort, total
aortic valve calcification volume was 643 ± 102mm3 and
989 ± 145mm3 in LFLGAS and non-LFLGAS patients (𝑝 =
0.07); total aortic valve calcificationmass was 398±61mg and
677 ± 105mg (𝑝 = 0.06) and total aortic valve calcification
density 755±20HU and 803±27HU (𝑝 = 0.16), respectively.
Maximal differences of calcification volumes and masses
between the three aortic cusps, a measure of calcification
asymmetry, were lower in LFLGAS (162.9 ± 16.8mm3 and
168.2± 59.0mg) compared to non-LFLGAS patients (286.6±
21.9mm3 and 234.2 ± 18.3mg; 𝑝 < 0.001).
Baseline mean aortic valve gradients correlated signifi-
cantly with aortic valve calcification volume (𝑟 = 0.42, 𝑝 ≤
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Table 1: Baseline characteristics.
Baseline characteristics Combined LFLGAS Non-LFLGAS 𝑝 value
Age, years 83 ± 0.5 81 ± 1.2 83 ± 0.5 0.07
Male 73 (53) 23 (68) 50 (49) 0.07
Coronary artery disease 91 (66) 25 (74) 66 (64) 0.40
Previous CABG 30 (22) 11 (32) 19 (18) 0.10
Diabetes mellitus 36 (26) 11 (32) 25 (24) 0.37
Hypertension 110 (80) 25 (74) 85 (83) 0.32
Cerebrovascular disease 37 (27) 7 (21) 30 (29) 0.38
Chronic obstructive pulmonary disease 21 (15) 5 (15) 16 (16) 1.00
Peripheral vascular disease 37 (27) 15 (44) 22 (21) 0.01
Pulmonary hypertension 19 (14) 7 (21) 12 (12) 0.25
Atrial fibrillation 35 (26) 14 (41) 21 (20) 0.02
Porcelain aorta 16 (12) 5 (15) 11 (11) 0.54
Creatinine (𝜇mol/L) 117 ± 5 112 ± 6 133 ± 3 0.14
STS-PROM score (%) 5.6 ± 0.3 5.3 ± 0.30 6.3 ± 0.7 0.24
LVEF (%) 55 ± 1.1 48 ± 2.7 57 ± 1.1 0.003
Mean aortic valve gradient (mmHg) 48 ± 1.4 29 ± 1.2 55 ± 1.4 <0.001
Stroke volume index (mL/m2) 31 ± 0.9 27 ± 0.9 32 ± 1.1 0.009
Aortic valve area (cm2) 0.72 ± 0.02 0.81 ± 0.04 0.69 ± 0.02 0.004
CABG: coronary artery bypass grafting, STS-PROM: Society of Thoracic Surgeons Predicted Risk of Mortality, and LVEF: left ventricular ejection fraction,
respectively. Results are presented as mean and standard error, or as number and percentages. 𝑝 ≤ 0.05 denotes a significant difference between patients with
low-flow low-gradient severe aortic stenosis (LFLGAS) and those with non-LFLGAS.
Table 2: Aortic valve calcification characteristics.
Parameters Combined LFLGAS Non-LFLGAS 𝑝 value
Total aortic valve
Calcification volume (mm3) 1106 ± 164 627 ± 61 1264 ± 216 <0.001
Calcification mass (mg) 660 ± 34 398 ± 39 747 ± 41 <0.001
Calcification density (HU) 817 ± 10 766 ± 18 834 ± 12 0.004
Noncoronary cusp
Calcification volume (mm3) 378 ± 20 222 ± 20 429 ± 24 <0.001
Calcification mass (mg) 282 ± 20 200 ± 60 309 ± 18 <0.001
Calcification density (HU) 810 ± 13 754 ± 20 852 ± 11 0.01
Right coronary cusp
Calcification volume (mm3) 272 ± 18 201 ± 26 295 ± 21 0.06
Calcification mass (mg) 186 ± 13 127 ± 17 206 ± 16 0.03
Calcification density (HU) 801 ± 10 752 ± 19 829 ± 16 0.004
Left coronary cusp
Calcification volume (mm3) 309 ± 22 204 ± 28 344 ± 27 0.01
Calcification mass (mg) 219 ± 17 127 ± 18 250 ± 21 <0.001
Calcification density (HU) 835 ± 10 785 ± 17 817 ± 11 0.003
𝑝 ≤ 0.05 denotes a significant difference between patients with low-flow low-gradient severe aortic stenosis (LFLGAS) and those with non-LFLGAS.
0.001), mass (𝑟 = 0.46, 𝑝 ≤ 0.001), and density (𝑟 = 0.29,
𝑝 = 0.001).
3.5. Symptomatic andHemodynamic Improvement at 30 Days.
At 30-day follow-up, mean transaortic pressure gradient was
8.8 ± 05mmHg in LFLGAS patients and 9.3 ± 0.5mmHg
in non-LFLGAS patients (𝑝 = 0.58). More than mild
paravalvular regurgitation at 30 days did not differ between
groups (Figure 2). In the LFLGAS group, 9/34 (26%) patients
had more than mild paravalvular regurgitation compared to
34/103 (33%) patients in the non-LFLGAS group (𝑝 = 0.52).
In both the LFLGAS and the non-LFLGASgroup, patients
with more than mild paravalvular regurgitation at 30 days
tended to have higher total aortic valve calcification volume
(708 ± 167mm3 versus 598 ± 60mm3, 𝑝 = 0.67 for LFLGAS,
and 1758±637mm3 versus 1021±69mm3, 𝑝 = 0.29 for non-
LFLGAS), mass (484 ± 110mg versus 367 ± 34mg, 𝑝 = 0.38
for LFLGAS, and 836±77mg versus 703±47mg,𝑝 = 0.17 for
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Figure 2: Postprocedural paravalvular aortic regurgitation in patients with low-flow low-gradient severe aortic stenosis (LFLGAS) and those
with non-LFLGAS. (a) LFLGAS patients. (b) Non-LFLGAS patients.
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Figure 3: Postprocedural symptomatic improvement in patients with low-flow low-gradient severe aortic stenosis (LFLGAS) and those with
non-LFLGAS. (a) LFLGAS patients. (b) Non-LFLGAS patients. NYHA indicates New York Heart Association functional class. 𝑝 ≤ 0.05
denotes a significant difference between patients with low-flow low-gradient severe aortic stenosis (LFLGAS) and those with non-LFLGAS.
non-LFLGAS), and density (818±40HU versus 747±18HU,
𝑝 = 0.07 for LFLGAS, and 867 ± 24HU versus 817 ± 12HU,
𝑝 = 0.10 for non-LFLGAS), albeit without reaching statistical
significance.
At baseline, 26/34 (77%) and 69/103 (67%) patients were
in New York Heart Association (NYHA) functional class III
or IV. A significant symptomatic improvement was observed
in both groups, with 5/24 (21%) LFLGAS patients and 8/73
(11%) non-LFLGAS patients in NYHA functional class III or
IV at 30-day follow-up (𝑝 < 0.001; Figure 3).
4. Discussion
This study demonstrates that calcification characteristics
differ between LFLGAS and non-LFLGAS patients, with less
calcification mass, volume, and asymmetry in the former
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compared to the latter. In both groups, a substantial symp-
tomatic and hemodynamic benefit after TAVR was observed
with comparable postprocedural THV function.
4.1. Low-Flow Low-Gradient Severe Aortic Stenosis. LFLGAS
is considered as distinct clinical entity, and the observed
prevalence of 25% in our patient cohort is in line with
previously reported data [8, 17]. In the era of emerging tran-
scatheter approaches, the optimal therapeutic strategy still
remains unclear. Substantial clinical benefits have recently
been reported in LFLGAS patients undergoing TAVR [23,
24], with reduced long-term mortality when compared to
medical management alone [24]. However, in this patient
subgroup, clinical outcomes following TAVR have not exten-
sively been studied yet, and inconsistencies do exist with
regard to benefits in comparison to high-gradient AS. While
low transaortic pressure gradients have clearly been asso-
ciated with an increased mortality in patients undergoing
TAVR [23, 25–27], a recent study reported comparable post-
procedural short- and long-term outcomes in patients with
LFLGAS and those with high-gradient AS,most interestingly,
irrespective of left ventricular systolic function [28]. In
line with these findings, similar outcomes after TAVR have
been reported in patients with low-gradient severe AS and
preserved LVEF and those with high-gradient severe AS [29].
Of note, low-flow states, and not impaired left ventricular
systolic function or low transvalvular gradients, have mainly
been suggested to add to the increased risk associated with
this challenging patients’ subset [24, 30]. Hence, optimal
postprocedural therapy and minimization of postprocedural
complications including paravalvular regurgitation are of
utmost importance in this patient population to further
reduce cardiovascular morbidity and mortality [28].
4.2. Importance of Aortic Valve Calcifications in THV. Pre-
procedural evaluation of aortic root characteristics is impor-
tant for procedure planning and often remains challenging
given the complex three-dimensional annular structure [31].
Mostly, preprocedural assessment is based on multimodal-
ity imaging including transthoracic and transesophageal
echocardiography as well as MDCT [32–36], with MDCT
being considered the imaging modality which provides the
most accurate measures of annular dimensions and calcifi-
cations [14, 37, 38]. In particular, utilizing MDCT for the
evaluation of calcifications, qualitative measurements of dif-
ferent calcification characteristics become possible compared
to a rather qualitative echocardiographic evaluation. In both
patient subgroups, a trend towards more severe aortic valve
calcifications in patients with more than mild paravalvular
regurgitation was observed, pointing towards the association
between annular calcifications and paravalvular regurgitation
after TAVR irrespective of AS disease entity.
As expected, aortic valves were highly calcified in this
patient cohort. Interestingly, patients with LFLGAS displayed
less severe aortic valve calcifications compared to those with
non-LFLGAS. These findings suggest that annular structures
may be unequally affected by fibrotic and/or calcific changes
in different AS disease entities. Indeed, low aortic valve gradi-
ents have been associated with increased myocardial fibrosis
in biopsy samples and more late-gadolinium enhancement
in magnetic resonance imaging studies [39]. Further, as
baseline mean aortic valve gradients correlated significantly
with aortic valve calcification severity in this patient cohort,
a cause-effect relationship between mechanical forces and
aortic valve calcifications may be hypothesized, and adverse
patterns of fluid shear stress may promote calcification pro-
cesses.This interpretation is supported by recent studies iden-
tifying baseline hemodynamic aortic stenosis severity as an
independent predictor of disease progression [40, 41]. Hence,
alteredmechanical forces associated with lower transvalvular
pressure gradients could at least in part explain lower degrees
of valvular calcifications observed in LFLGAS patients. As
AVA was larger in LFLGAS patients, some have speculated
that this disease entity represents a precursor of high-gradient
aortic stenosis. However, the fact that similar trends towards
higher calcifications in non-LFLGAS patients were observed
in patientsmatched forAVA suggests that possible differences
in AS severity as assessed by AVA may not fully explain the
different degree of valvular calcifications observed among
groups. However, we cannot exclude completely that slightly
different AS severities as reflected by significantly different
AVA between LFLGAS and non-LFLGAS patients may at
least in part have contributed to the observed findings. How-
ever, pathophysiological considerations remain speculative
in this context, and further large-scale clinical studies are
needed to elucidate key pathological mechanisms underlying
these observations.
4.3. Study Limitations. There are some limitations that need
to be considered such as the single center design, the retro-
spective nature, and the rather small patient population. In
particular, larger studies are needed to allow for comparisons
among different LFLGAS subgroups and to elucidate the
association between calcifications and paravalvular regurgi-
tation in LFLGAS and non-LFLGAS patients. In addition,
the comparison of patients with and without flow reserve
was precluded, as dobutamine stress echocardiography was
not performed in the entire patient cohort. This study
was designed to assess calcification characteristics and their
impact on postprocedural THV function and, thus, included
patients with preprocedural MDCT and postprocedural
echocardiography within 30 days, a design which did not
allow for a comparison of mortality rates among groups.
5. Conclusion
This study demonstrates that aortic valve calcification char-
acteristics vary between patients with LFLGAS and non-
LFLGAS with less valvular calcification mass, volume, and
asymmetry observed in the former. These observations
evidence the unmet need for further characterization and
stratification of this challengingAS patients’ subgroup aiming
at an enhanced understanding of different AS disease enti-
ties. Importantly, substantial symptomatic and hemodynamic
benefit was observed in both patient groups with excellent
postprocedural THV function.
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